Physician profile
Andrew Decker
NPI 1548829336
$4,126.78
in general payments reported to CMS, 2019-2025
23 companies · $959 in 2025
The $959 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,154 · 2022: $886 · 2023: $602 · 2024: $526 · 2025: $959.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,087.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,086.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,559.89 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $472.17 | 2021-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $468.83 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Indivior INC. | $400.10 | 2024-2025 | Sublocade |
| Takeda Pharmaceuticals U.S.A., INC. | $216.73 | 2021-2022 | |
| Novo Nordisk INC | $169.35 | 2021-2024 | Rybelsus, Ozempic |
| Lilly USA, LLC | $154.01 | 2021-2025 | Mounjaro |
| Amgen INC. | $117.55 | 2022-2025 | Otezla, Repatha, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $107.54 | 2023-2025 | |
| Pfizer INC. | $79.50 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $75.52 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $54.36 | 2021 | |
| Axsome Therapeutics, INC. | $44.03 | 2022-2023 | Auvelity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $33.52 | 2024 | Trulance, Xifaxan |
| Inspire Medical Systems, INC. | $29.96 | 2025 | Inspire |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $25.37 | 2025 | Dexcom G6 Transmitter |
| Alkermes, INC. | $19.60 | 2025 | Lybalvi |
| Cranial Technologies, INC | $19.41 | 2024 | Doc Band |
| Teva Pharmaceuticals USA, INC. | $17.75 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.62 | 2025 | Caplyta |
| Mannkind Corporation | $17.40 | 2021 | |
| Redhill Biopharma INC. | $14.33 | 2021 | |
| Glaxosmithkline, LLC. | $12.24 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Decker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.